The overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 20% of breast cancers [1] and 20% of gastric cancers [2], which are associated with higher rates of recurrence and shorter overall survival. Here, ERBB2 is linked to breast cancer.